Vimarsana
Biggest News Aggregation in the World

Page 42 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study | Comunicados | Edición USA - Vimarsana News

Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study | Comunicados | Edición USA

22 abr 2021 Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study SHANGHAI, China, April 22, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Independent Data Monitoring Committee (IDMC) has determined that toripalimab in combination with paclitaxel/cisplatin as the first-line treatment for patients with advanced esophageal squ...

Source: efe.com
Junshi Biosciences: Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study - Vimarsana News

Junshi Biosciences: Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study

(0) SHANGHAI, China, April 22, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Independent Data Monitoring Committee (IDMC) has determined that toripalimab in combination with paclitaxel/cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) has reached its pre-specified primary endpoints of Progression Free Survival (PFS) and Overall Survival (OS) at the inter...

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Announces Rights Offering - Vimarsana News

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Announces Rights Offering

  Founded in 1987, Etalon Group is one of the largest development and construction companies in Russia. The Company focuses on middle class residential real estate in the Moscow and St Petersburg metropolitan areas. With a more than 30-year history, Etalon Group has one of the longest and most successful track records in the Russian real estate industry. Since its foundation, Etalon Group has commissioned 7.5 million sqm of real estate.   The Company is vertically integrated, which helps it to control costs, quality and timing, as well as maintain best-in-class profi...

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Group Announces 1Q 2021 Operating Results - Vimarsana News

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Group Announces 1Q 2021 Operating Results

  "The slight decrease in sales volumes in 1Q 2021, following record results a year ago, is primarily due to the lower volume of real estate available for sale. The temporary shortage of supply had an insignificant impact on year-to-year performance indicators: new contract sales in the first three months of 2021 amounted to over RUB 16 billion. The average price per square metre rose 15% year-on-year to RUB 164 ths, generating RUB 18 billion in cash collections.   "In line with our plans to increase supply, we will be launching sales for the ZIL-Yug project and for...

NMPA Approves Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma - Vimarsana News

NMPA Approves Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Published: Apr 12, 2021 SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-contain...